<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153018">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01886690</url>
  </required_header>
  <id_info>
    <org_study_id>11002X-002</org_study_id>
    <nct_id>NCT01886690</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety and efficacy of a new eye drop formulation with REFRESH
      PLUS® in participants following LASIK surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ocular Surface Disease Index© (OSDI) Score using a 5-Point Scale</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Break-up Time (TBUT)</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer Test</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Bilateral LASIK Surgery</condition>
  <arm_group>
    <arm_group_label>New Eye Drop Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye  as per protocol for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REFRESH PLUS®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboxymethylcellulose sodium based new eye drop formulation</intervention_name>
    <description>1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye  as per protocol for 90 days.</description>
    <arm_group_label>New Eye Drop Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboxymethylcellulose sodium based eye drops</intervention_name>
    <description>1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.</description>
    <arm_group_label>REFRESH PLUS®</arm_group_label>
    <other_name>REFRESH PLUS®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients scheduled for LASIK surgery in both eyes.

        Exclusion Criteria:

          -  Any systemic medication use within 3 months of screening (including over the counter,
             herbal, prescription, or nutritional supplement) which may affect dry eye or vision

          -  Use of topical eye medication other than prescribed for use in pre- or post-operative
             care

          -  Use of RESTASIS® or other topical ophthalmic cyclosporine product within 6 months
             prior to Screening

          -  Eye infection, inflammation, or allergy

          -  Soft contact lenses in the previous 7 days or rigid contact lenses in the previous 30
             days prior to LASIK surgery.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>New South Wales</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
